GlaxoSmithKline plc Stock Price, News & Analysis (NYSE:GSK)

$35.04 -0.02 (-0.06 %)
(As of 11/24/2017 04:21 AM ET)
Previous Close$35.06
Today's Range$34.97 - $35.19
52-Week Range$34.72 - $44.53
Volume1.74 million shs
Average Volume5.03 million shs
Market Capitalization$86.22 billion
P/E Ratio12.43
Dividend Yield5.69%
Beta1

About GlaxoSmithKline plc (NYSE:GSK)

GlaxoSmithKline plc logoGlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines, vaccines and consumer healthcare products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health categories. Its product portfolio includes Adartrel, Bexsero, Daraprim and Quinvaxem. Its brands include Panadol, abreva, polident and physiogel.

Receive GSK News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNYSE:GSK
CUSIPN/A
Phone44-20-8047-5000

Debt

Debt-to-Equity Ratio2.96%
Current Ratio0.64%
Quick Ratio0.44%

Price-To-Earnings

Trailing P/E Ratio12.43
Forward P/E Ratio12.12
P/E Growth1.94

Sales & Book Value

Annual Sales$37.82 billion
Price / Sales2.28
Cash Flow$4.00 per share
Price / Cash8.77
Book Value$2.57 per share
Price / Book13.63

Profitability

Trailing EPS$1.22
Net Income$1.24 billion
Net Margins7.79%
Return on Equity115.30%
Return on Assets9.69%

Miscellaneous

Employees99,827
Outstanding Shares2,459,340,000

Frequently Asked Questions for GlaxoSmithKline plc (NYSE:GSK)

What is GlaxoSmithKline plc's stock symbol?

GlaxoSmithKline plc trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

How often does GlaxoSmithKline plc pay dividends? What is the dividend yield for GlaxoSmithKline plc?

GlaxoSmithKline plc declared a quarterly dividend on Thursday, October 26th. Shareholders of record on Friday, November 10th will be paid a dividend of $0.5037 per share on Thursday, January 11th. This represents a $2.01 dividend on an annualized basis and a dividend yield of 5.75%. The ex-dividend date is Thursday, November 9th. This is a positive change from GlaxoSmithKline plc's previous quarterly dividend of $0.49. View GlaxoSmithKline plc's Dividend History.

How were GlaxoSmithKline plc's earnings last quarter?

GlaxoSmithKline plc (NYSE:GSK) posted its earnings results on Wednesday, July, 29th. The pharmaceutical company reported $0.53 earnings per share for the quarter, topping analysts' consensus estimates of $0.50 by $0.03. The pharmaceutical company had revenue of $9.02 billion for the quarter, compared to analyst estimates of $9.14 billion. GlaxoSmithKline plc had a net margin of 7.79% and a return on equity of 115.30%. View GlaxoSmithKline plc's Earnings History.

When will GlaxoSmithKline plc make its next earnings announcement?

GlaxoSmithKline plc is scheduled to release their next quarterly earnings announcement on Wednesday, February, 14th 2018. View Earnings Estimates for GlaxoSmithKline plc.

Where is GlaxoSmithKline plc's stock going? Where will GlaxoSmithKline plc's stock price be in 2017?

15 brokers have issued twelve-month price objectives for GlaxoSmithKline plc's stock. Their forecasts range from $37.00 to $50.00. On average, they anticipate GlaxoSmithKline plc's share price to reach $43.50 in the next twelve months. View Analyst Ratings for GlaxoSmithKline plc.

Are investors shorting GlaxoSmithKline plc?

GlaxoSmithKline plc saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 14,380,912 shares, an increase of 76.8% from the October 13th total of 8,134,960 shares. Based on an average daily volume of 7,703,941 shares, the days-to-cover ratio is presently 1.9 days. Approximately 0.6% of the shares of the company are sold short.

Who are some of GlaxoSmithKline plc's key competitors?

Who are GlaxoSmithKline plc's key executives?

GlaxoSmithKline plc's management team includes the folowing people:

  • Emma Walmsley, Chief Executive Officer, Executive Director
  • Simon Dingemans, Chief Financial Officer, Executive Director
  • Patrick Vallance, President - R&D, Executive Director
  • Roger Connor, President - Global Manufacturing & Supply
  • , Bio & Compensation - 
  • Luc Debruyne, President - Global Vaccines
  • , Bio & Compensation - 
  • Abbas Hussain, President - Global Pharmaceuticals
  • , Bio & Compensation - 
  • Shah Abbas Hussain, President - Global Pharmaceuticals
  • , Bio & Compensation - 
  • Brian McNamara, Chief Executive Officer - GSK Consumer Healthcare
  • Luke Miels, President - Global Pharmaceuticals
  • , Bio & Compensation - 
  • Daniel E. Troy, Senior Vice President, General Counsel
  • , Bio & Compensation - 

Who owns GlaxoSmithKline plc stock?

GlaxoSmithKline plc's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.52%), Hotchkis & Wiley Capital Management LLC (0.34%), Bank of New York Mellon Corp (0.24%), NWQ Investment Management Company LLC (0.11%), Equity Investment Corp (0.10%) and Macquarie Group Ltd. (0.10%). View Institutional Ownership Trends for GlaxoSmithKline plc.

Who sold GlaxoSmithKline plc stock? Who is selling GlaxoSmithKline plc stock?

GlaxoSmithKline plc's stock was sold by a variety of institutional investors in the last quarter, including Brandes Investment Partners LP, OLD Republic International Corp, Saturna Capital CORP, Macquarie Group Ltd., Miller Howard Investments Inc. NY, Nationwide Fund Advisors, Kahn Brothers Group Inc. DE and Kornitzer Capital Management Inc. KS. View Insider Buying and Selling for GlaxoSmithKline plc.

Who bought GlaxoSmithKline plc stock? Who is buying GlaxoSmithKline plc stock?

GlaxoSmithKline plc's stock was acquired by a variety of institutional investors in the last quarter, including Hotchkis & Wiley Capital Management LLC, Point72 Asset Management L.P., Seatown Holdings Pte. Ltd., Fisher Asset Management LLC, NWQ Investment Management Company LLC, Sector Gamma AS, Sei Investments Co. and Crossmark Global Holdings Inc.. View Insider Buying and Selling for GlaxoSmithKline plc.

How do I buy GlaxoSmithKline plc stock?

Shares of GlaxoSmithKline plc can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GlaxoSmithKline plc's stock price today?

One share of GlaxoSmithKline plc stock can currently be purchased for approximately $35.04.

How big of a company is GlaxoSmithKline plc?

GlaxoSmithKline plc has a market capitalization of $86.22 billion and generates $37.82 billion in revenue each year. The pharmaceutical company earns $1.24 billion in net income (profit) each year or $1.22 on an earnings per share basis. GlaxoSmithKline plc employs 99,827 workers across the globe.

How can I contact GlaxoSmithKline plc?

GlaxoSmithKline plc's mailing address is 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected]


MarketBeat Community Rating for GlaxoSmithKline plc (GSK)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  328 (Vote Outperform)
Underperform Votes:  664 (Vote Underperform)
Total Votes:  992
MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for GlaxoSmithKline plc (NYSE:GSK)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.222.292.392.48
Ratings Breakdown: 3 Sell Rating(s)
12 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
11 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
10 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
11 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $45.75$45.75$46.00$46.00
Price Target Upside: 26.66% upside25.00% upside16.57% upside8.06% upside

Consensus Price Target History for GlaxoSmithKline plc (NYSE:GSK)

Price Target History for GlaxoSmithKline plc (NYSE:GSK)

Analysts' Ratings History for GlaxoSmithKline plc (NYSE:GSK)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/6/2017InvestecDowngradeBuy -> HoldN/AView Rating Details
10/26/2017Bank of America CorporationDowngradeBuy -> NeutralN/AView Rating Details
10/24/2017J P Morgan Chase & CoReiterated RatingNeutralN/AView Rating Details
9/8/2017Morgan StanleyDowngradeEqual Weight -> UnderweightLowView Rating Details
8/31/2017ArgusReiterated RatingBuy$50.00LowView Rating Details
7/27/2017Citigroup Inc.Reiterated RatingNeutralLowView Rating Details
5/26/2017Berenberg BankUpgradeHold -> BuyLowView Rating Details
4/6/2017BNP ParibasLower Price Target$37.00LowView Rating Details
4/5/2017Exane BNP ParibasUpgradeUnderperform -> NeutralLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageBuy -> BuyLowView Rating Details
3/9/2017Kepler Capital MarketsInitiated CoverageReduce -> ReduceLowView Rating Details
3/7/2017Barclays PLCInitiated CoverageEqual WeightN/AView Rating Details
2/19/2017Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
2/9/2017Deutsche Bank AGReiterated RatingNeutralN/AView Rating Details
12/27/2016Goldman Sachs Group IncReiterated RatingBuyN/AView Rating Details
10/26/2016Beaufort SecuritiesReiterated RatingBuyN/AView Rating Details
9/23/2016Piper Jaffray CompaniesInitiated CoverageOverweightN/AView Rating Details
8/17/2016Shore CapitalReiterated RatingHoldN/AView Rating Details
5/26/2016Cowen IncDowngradeOutperform -> Market PerformN/AView Rating Details
5/5/2016Oddo SecuritiesUpgradeReduce -> BuyN/AView Rating Details
2/26/2016Cantor FitzgeraldInitiated CoverageHoldN/AView Rating Details
2/4/2016Sanford C. BernsteinBoost Price TargetMarket Perform$43.00 -> $45.00N/AView Rating Details
1/27/2016Bryan, Garnier & CoUpgradeNeutral -> BuyN/AView Rating Details
12/21/2015Leerink SwannReiterated RatingMarket Perform$48.00N/AView Rating Details
(Data available from 11/25/2015 forward)

Earnings

Earnings History and Estimates Chart for GlaxoSmithKline plc (NYSE:GSK)

Earnings by Quarter for GlaxoSmithKline plc (NYSE:GSK)

Earnings History by Quarter for GlaxoSmithKline plc (NYSE GSK)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2018        
7/26/20176/30/2017$0.68$0.70$9.52 billion$9.36 billionViewN/AView Earnings Details
4/26/20173/31/2017$0.62$0.62$9.09 billion$9.23 billionViewN/AView Earnings Details
2/8/201712/31/2016$0.57$0.65$9.21 billion$9.43 billionViewListenView Earnings Details
10/26/2016Q316$0.77$0.83$8.92 billion$9.90 billionViewListenView Earnings Details
10/28/2015Q3$0.60$0.71$6.07 billion$6.13 billionViewN/AView Earnings Details
7/29/2015Q215$0.50$0.53$9.14 billion$9.02 billionViewN/AView Earnings Details
5/6/2015Q115$0.55$0.48$8.55 billion$8.51 billionViewN/AView Earnings Details
2/4/2015Q414$0.86$0.82$6.14 billion$6.19 billionViewN/AView Earnings Details
10/22/2014Q314$0.79$0.90$9.76 billion$9.12 billionViewListenView Earnings Details
7/23/2014Q114$0.71$0.65$10.13 billion$9.47 billionViewN/AView Earnings Details
4/30/2014Q413$0.72$0.70$10.36 billion$9.44 billionViewN/AView Earnings Details
2/5/2014Q4$0.30$0.30$6.84 billion$6.91 billionViewN/AView Earnings Details
10/23/2013Q313$0.31$10.31 billion$10.09 billionViewN/AView Earnings Details
7/24/2013$0.26$0.26$6.62 billionViewN/AView Earnings Details
4/25/2012$0.29$0.27ViewN/AView Earnings Details
2/7/2012$0.30$0.28ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for GlaxoSmithKline plc (NYSE:GSK)
2017 EPS Consensus Estimate: $2.78
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.59$0.63$0.61
Q2 20171$0.71$0.71$0.71
Q3 20172$0.81$0.86$0.84
Q4 20171$0.62$0.62$0.62
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for GlaxoSmithKline plc (NYSE:GSK)

Next Dividend:1/11/2018
Annual Dividend:$1.99
Dividend Yield:5.68%
Dividend Growth:-3.10% (3 Year Average)
Payout Ratio:163.12% (Trailing 12 Months of Earnings)
68.86% (Based on This Year's Estimates)
70.82% (Based on Next Year's Estimates)
Frequency:Quarterly Dividend
Dividend Payments by Quarter for GlaxoSmithKline plc (NYSE:GSK)

Dividend History by Quarter for GlaxoSmithKline plc (NYSE GSK)

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/26/2017quarterly$0.505.51%11/9/201711/10/20171/11/2018
7/26/2017Quarterly$0.494.88%8/9/20178/11/201710/12/2017
4/26/2017quarterly$0.484.79%5/10/20175/12/20177/13/2017
2/8/2017quarterly$0.575.76%2/22/20172/24/20174/13/2017
10/26/2016$0.4611/2/201611/4/20161/12/2017
7/27/2016$0.498/10/20168/12/201610/13/2016
4/28/2016$0.555/11/20165/13/20167/14/2016
10/28/2015$0.5811/10/201511/13/20151/14/2016
5/7/2015quarterly$0.585.22%5/13/20155/15/20157/9/2015
2/5/2015quarterly$0.706.05%2/18/20152/20/20154/9/2015
10/23/2014quarterly$0.615.41%11/5/201411/7/20141/8/2015
7/24/2014quarterly$0.655.18%8/6/20148/8/201410/2/2014
5/1/2014quarterly$0.644.62%5/14/20145/16/20147/10/2014
2/5/2014$0.752/19/20142/21/20144/10/2014
2/6/2014quarterly$0.755.73%2/19/20142/21/20144/10/2014
10/24/2013quarterly$0.624.76%11/13/201311/15/20131/9/2014
7/25/2013quarterly$0.554.27%8/7/20138/9/201310/3/2013
4/25/2013quarterly$0.554.25%5/8/20135/10/20137/11/2013
2/7/2013quarterly$0.070.61%2/20/20132/22/20134/11/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for GlaxoSmithKline plc (NYSE GSK)

Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 9.84%
Insider Trades by Quarter for GlaxoSmithKline plc (NYSE:GSK)
Institutional Ownership by Quarter for GlaxoSmithKline plc (NYSE:GSK)

Insider Trades by Quarter for GlaxoSmithKline plc (NYSE GSK)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/6/2017Plc GlaxosmithklineMajor ShareholderBuy428,571$14.00$5,999,994.00View SEC Filing  
10/24/2016Plc GlaxosmithklineMajor ShareholderBuy66,500$14.00$931,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for GlaxoSmithKline plc (NYSE GSK)

Source:
DateHeadline
Here"s How Walmsley Just Completed a Clean Sweep at GlaxoSmithKlineHere"s How Walmsley Just Completed a Clean Sweep at GlaxoSmithKline
finance.yahoo.com - November 24 at 4:45 PM
GlaxoSmithKline, Innoviva File For Supplementary NDA For Trelegy ElliptaGlaxoSmithKline, Innoviva File For Supplementary NDA For Trelegy Ellipta
www.rttnews.com - November 23 at 4:42 PM
A Look into the Performance of Merck’s Vaccine Portfolio in 3Q17A Look into the Performance of Merck’s Vaccine Portfolio in 3Q17
finance.yahoo.com - November 22 at 8:06 PM
Novartis (NVS) Receives EC Nod for Tasigna Label ExpansionNovartis (NVS) Receives EC Nod for Tasigna Label Expansion
finance.yahoo.com - November 22 at 8:06 PM
U.S. FDA approves first two-drug HIV regimen in win for GSKU.S. FDA approves first two-drug HIV regimen in win for GSK
finance.yahoo.com - November 22 at 5:34 AM
ViiV Healthcare says FDA has approved its two-drug HIV regimen, in first such instanceViiV Healthcare says FDA has approved its two-drug HIV regimen, in first such instance
finance.yahoo.com - November 21 at 7:16 PM
U.S. FDA approves first two-drug HIV regimen from GSKU.S. FDA approves first two-drug HIV regimen from GSK
finance.yahoo.com - November 21 at 7:16 PM
Is GlaxoSmithKline plc (LSE:GSK) Undervalued?Is GlaxoSmithKline plc (LSE:GSK) Undervalued?
finance.yahoo.com - November 20 at 7:47 PM
Slumping Earnings Visibility Make GlaxoSmithKline (GSK) a Sell - Investorplace.comSlumping Earnings Visibility Make GlaxoSmithKline (GSK) a Sell - Investorplace.com
investorplace.com - November 18 at 6:27 PM
FDA Nod For Label Expansion Of Sutent, Egalet Flies, Double Blessing For RocheFDA Nod For Label Expansion Of Sutent, Egalet Flies, Double Blessing For Roche
www.rttnews.com - November 17 at 11:50 AM
GlaxoSmithKline PLC (GSK) Given Average Recommendation of "Hold" by BrokeragesGlaxoSmithKline PLC (GSK) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 16 at 5:06 PM
[$$] Gates Foundation, Abu Dhabi Pair to Fight Forgotten Diseases[$$] Gates Foundation, Abu Dhabi Pair to Fight Forgotten Diseases
finance.yahoo.com - November 16 at 2:53 PM
Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Gains Marketing Authorisation in Europe for the Treatment of COPDTrelegy Ellipta Once-Daily Single Inhaler Triple Therapy Gains Marketing Authorisation in Europe for the Treatment of COPD
finance.yahoo.com - November 16 at 2:53 PM
Europe approves GlaxoSmithKlines new triple lung drugEurope approves GlaxoSmithKline's new triple lung drug
finance.yahoo.com - November 16 at 2:53 PM
 Brokerages Anticipate GlaxoSmithKline PLC (GSK) Will Post Quarterly Sales of $9.89 Billion Brokerages Anticipate GlaxoSmithKline PLC (GSK) Will Post Quarterly Sales of $9.89 Billion
www.americanbankingnews.com - November 16 at 2:18 AM
GlaxoSmithKline PLC (GSK) and Tetraphase Pharmaceuticals (TTPH) Financial ComparisonGlaxoSmithKline PLC (GSK) and Tetraphase Pharmaceuticals (TTPH) Financial Comparison
www.americanbankingnews.com - November 15 at 7:14 AM
$0.64 EPS Expected for GlaxoSmithKline PLC (GSK) This Quarter$0.64 EPS Expected for GlaxoSmithKline PLC (GSK) This Quarter
www.americanbankingnews.com - November 14 at 11:20 PM
Dodge & Cox Buys Eli Lilly and Co, Micro Focus International PLC, Gilead Sciences Inc, ...Dodge & Cox Buys Eli Lilly and Co, Micro Focus International PLC, Gilead Sciences Inc, ...
www.nasdaq.com - November 14 at 7:50 PM
GlaxoSmithKline PLC (GSK) Sees Large Increase in Short InterestGlaxoSmithKline PLC (GSK) Sees Large Increase in Short Interest
www.americanbankingnews.com - November 14 at 3:58 AM
ETFs with exposure to GlaxoSmithKline Plc : November 13, 2017ETFs with exposure to GlaxoSmithKline Plc : November 13, 2017
finance.yahoo.com - November 13 at 7:21 PM
Bill Gates Is Now Tackling Alzheimer’s With a Huge Investment in Dementia ResearchBill Gates Is Now Tackling Alzheimer’s With a Huge Investment in Dementia Research
finance.yahoo.com - November 13 at 9:25 AM
GlaxoSmithKline Plc : GSK-US: Dividend Analysis : November 10th, 2017 (record date) : By the numbers : November 10, 2017GlaxoSmithKline Plc : GSK-US: Dividend Analysis : November 10th, 2017 (record date) : By the numbers : November 10, 2017
finance.yahoo.com - November 12 at 10:06 AM
Head-To-Head Review: GlaxoSmithKline PLC (GSK) vs. The CompetitionHead-To-Head Review: GlaxoSmithKline PLC (GSK) vs. The Competition
www.americanbankingnews.com - November 9 at 3:52 PM
Hikma, Vectura in dispute with FDA over generic AdvairHikma, Vectura in dispute with FDA over generic Advair
finance.yahoo.com - November 9 at 6:19 AM
Heres What Cost GlaxoSmithKline PLC Nearly $10 Billion in Market Cap in OctoberHere's What Cost GlaxoSmithKline PLC Nearly $10 Billion in Market Cap in October
www.fool.com - November 8 at 12:19 PM
GlaxoSmithKline PLC (GSK) Major Shareholder Plc Glaxosmithkline Acquires 428,571 SharesGlaxoSmithKline PLC (GSK) Major Shareholder Plc Glaxosmithkline Acquires 428,571 Shares
www.americanbankingnews.com - November 8 at 12:22 AM
GlaxoSmithKline PLC (GSK) Downgraded to Hold at InvestecGlaxoSmithKline PLC (GSK) Downgraded to Hold at Investec
www.americanbankingnews.com - November 6 at 11:38 AM
Stock of GlaxoSmithKline (GSK) Lowered to Sell - Investorplace.comStock of GlaxoSmithKline (GSK) Lowered to Sell - Investorplace.com
investorplace.com - November 4 at 2:17 AM
Head to Head Review: GlaxoSmithKline PLC (GSK) vs. Its CompetitorsHead to Head Review: GlaxoSmithKline PLC (GSK) vs. Its Competitors
www.americanbankingnews.com - November 2 at 8:42 AM
Brokers Issue Forecasts for GlaxoSmithKline PLCs FY2017 Earnings (GSK)Brokers Issue Forecasts for GlaxoSmithKline PLC's FY2017 Earnings (GSK)
www.americanbankingnews.com - November 2 at 6:24 AM
Innoviva (INVA) Announces GSK (GSK) Study Demonstrates Superiority of Anoro Ellipta to Stiolto Respimat in Improving Lung Function in COPDInnoviva (INVA) Announces GSK (GSK) Study Demonstrates Superiority of Anoro Ellipta to Stiolto Respimat in Improving Lung Function in COPD
www.streetinsider.com - November 1 at 10:16 PM
GSK Study Demonstrates Superiority of Anoro Ellipta to Stiolto Respimat in Improving Lung Function in Chronic Obstructive Pulmonary DiseaseGSK Study Demonstrates Superiority of Anoro Ellipta to Stiolto Respimat in Improving Lung Function in Chronic Obstructive Pulmonary Disease
finance.yahoo.com - November 1 at 10:16 PM
ETFs with exposure to GlaxoSmithKline Plc : November 1, 2017ETFs with exposure to GlaxoSmithKline Plc : November 1, 2017
finance.yahoo.com - November 1 at 10:16 PM
GlaxoSmithKline PLC to Post FY2018 Earnings of $2.80 Per Share, Jefferies Group Forecasts (GSK)GlaxoSmithKline PLC to Post FY2018 Earnings of $2.80 Per Share, Jefferies Group Forecasts (GSK)
www.americanbankingnews.com - November 1 at 5:14 PM
Why GlaxoSmithKline plc is a growth bargain I’d buy and hold for 25 yearsWhy GlaxoSmithKline plc is a growth bargain I’d buy and hold for 25 years
www.fool.co.uk - October 31 at 8:39 PM
10 Cheap Foreign Stocks With Moats10 Cheap Foreign Stocks With Moats
finance.yahoo.com - October 30 at 8:08 PM
GlaxoSmithKline Plc :GSK-US: Earnings Analysis: Q3, 2017 By the Numbers : October 30, 2017GlaxoSmithKline Plc :GSK-US: Earnings Analysis: Q3, 2017 By the Numbers : October 30, 2017
finance.yahoo.com - October 30 at 8:08 PM
GlaxoSmithKline PLC (GSK) Raised to "B" at TheStreetGlaxoSmithKline PLC (GSK) Raised to "B" at TheStreet
www.americanbankingnews.com - October 28 at 10:52 PM
GlaxoSmithKline plc Expected to Post FY2017 Earnings of $2.76 Per Share (GSK)GlaxoSmithKline plc Expected to Post FY2017 Earnings of $2.76 Per Share (GSK)
www.americanbankingnews.com - October 27 at 8:34 AM
GlaxoSmithKline Cant Have it AllGlaxoSmithKline Can't Have it All
finance.yahoo.com - October 27 at 3:11 AM
CDCs Advisory Committee on Immunization Practices recommends Shingrix as the preferred vaccine for the prevention of shingles for adults aged 50 and upCDC's Advisory Committee on Immunization Practices recommends Shingrix as the preferred vaccine for the prevention of shingles for adults aged 50 and up
finance.yahoo.com - October 27 at 3:11 AM
Pfizer to Sell Consumer Healthcare Business Next MonthPfizer to Sell Consumer Healthcare Business Next Month
finance.yahoo.com - October 27 at 3:11 AM
Could GlaxoSmithKline Scoop Up Pfizer's Over-The-Counter Unit?Could GlaxoSmithKline Scoop Up Pfizer's Over-The-Counter Unit?
finance.yahoo.com - October 27 at 3:11 AM
PRESS DIGEST- British Business - Oct 26PRESS DIGEST- British Business - Oct 26
finance.yahoo.com - October 27 at 3:10 AM
Glaxo (GSK) Q3 Earnings Beat, Revenues In Line, Shares DownGlaxo (GSK) Q3 Earnings Beat, Revenues In Line, Shares Down
finance.yahoo.com - October 27 at 3:10 AM
GlaxoSmithKline PLC (GSK) Plans Quarterly Dividend of $0.50GlaxoSmithKline PLC (GSK) Plans Quarterly Dividend of $0.50
www.americanbankingnews.com - October 26 at 6:30 PM
GlaxoSmithKline PLC (GSK) Releases  Earnings Results, Misses Estimates By $0.57 EPSGlaxoSmithKline PLC (GSK) Releases Earnings Results, Misses Estimates By $0.57 EPS
www.americanbankingnews.com - October 25 at 4:52 PM
Q4 2017 EPS Estimates for GlaxoSmithKline PLC Reduced by Leerink Swann (GSK)Q4 2017 EPS Estimates for GlaxoSmithKline PLC Reduced by Leerink Swann (GSK)
www.americanbankingnews.com - October 25 at 11:04 AM
Should You Buy GlaxoSmithKline (GSK) Ahead of Earnings?Should You Buy GlaxoSmithKline (GSK) Ahead of Earnings?
finance.yahoo.com - October 25 at 3:07 AM
Analysts Offer Predictions for GlaxoSmithKline PLCs FY2017 Earnings (GSK)Analysts Offer Predictions for GlaxoSmithKline PLC's FY2017 Earnings (GSK)
www.americanbankingnews.com - October 24 at 8:30 AM

Social Media

Financials

Financials are not available for this stock.

Chart

GlaxoSmithKline plc (NYSE GSK) Chart for Saturday, November, 25, 2017
Loading chart…

This page was last updated on 11/25/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.